Here, we provide experimental evidence that the miR-34a–AXL axis is critical for the regulation of VM formation via the regulation of EMT, and it may serve as a potential therapeutic target to overcome the limitations of anti-angiogenic therapy in breast cancer. This evidence concerns the gene AXL and breast cancer.